knowledge -WSS

knowledge

author：explore 2025-09-27 07:51:36 - browse：6

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

explore

WSS

Air quality improving but still lags in Black, Hispanic communities

With trial win, GSK could get blood cancer drug back on market

Headspace, Meta partner to launch VR meditation app for Quest

Sen. Paul opposes bill to ban Chinese biotechs

FDA's Pazdur wants cancer trials to range beyond China alone

What it’s like to watch children die of measles

Wikipedia

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

Sen. Paul opposes bill to ban Chinese biotechs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia reports positive results for its CRISPR

In Memoriam: Notable people who died in 2023

With trial win, GSK could get blood cancer drug back on market

State Dept. review finds Biden bears some blame for Afghanistan failures

What it’s like to watch children die of measles

Malaria cases in Florida and Texas: Here’s what you need to know

With trial win, GSK could get blood cancer drug back on market

focus

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Intellia reports positive results for its CRISPR

Just how do doctors, lawmakers, and the public define abortion?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Air quality improving but still lags in Black, Hispanic communities

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

focus

explore

explore

hotspot